Skip to main content
SpringerLink
Log in

Future therapies for hepatitis C

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Therapy for hepatitis C is a dynamic field. Many new therapeutic agents, acting on different viral targets, are being developed for use. Some agents have been abandoned because of lack of efficacy or toxicity, but others have shown promise in preliminary studies and are being tested further, both as monotherapy and in combination with interferon or ribavirin, the current standard of care. Still others are in preclinical development. This article discusses new treatments that have shown efficacy in preliminary trials, with a particular emphasis on agents that have progressed to phase II and phase III trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Fried MW, Shiffman ML, Reddy KR, et al.: Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.

    Article  PubMed  CAS  Google Scholar 

  2. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.

    Article  PubMed  CAS  Google Scholar 

  3. Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265–2271.

    Article  PubMed  CAS  Google Scholar 

  4. Jeffers LJ, Cassidy W, Howell CD, et al.: Peginterferon alfa- 2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004, 39:1702–1708.

    Article  PubMed  CAS  Google Scholar 

  5. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438–450.

    Article  PubMed  CAS  Google Scholar 

  6. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002, 19:1–46.

    Google Scholar 

  7. Davis GL, Wong JB, McHutchison JG, et al.: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645–652.

    Article  PubMed  CAS  Google Scholar 

  8. Hinrichsen H, Benhamou Y, Wedemeyer H, et al.: Shortterm antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004, 127:1347–1355. The first study to show proof of principle of the efficacy of protease inhibitors. Although the trials for BILN 2061 were suspended because of toxicity, it paved the way for the development of similar agents.

    Article  PubMed  CAS  Google Scholar 

  9. Press Release. Hepatitis C Drug Development at Boehringer Ingelheim. http://us.boehringer-ingelheim.com/about/pressreleases/ 102803_hepatitis.html. Accessed May 26, 2006.

  10. Reesink HW, Zeuzem S, van Vliet A, et al.: Initial results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor [abstract]. Paper presented at Digestive Disease Week, Chicago, IL, May 14-19, 2005. Abstract 527.

  11. Malcolm BA, Liu R, Lahser F, et al.: SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006, 50:1013–1020.

    Article  PubMed  CAS  Google Scholar 

  12. Zeuzem S, Sarrazin C, Rouzier R, et al.: Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (@#@ Peg-IFN-α @#@) [abstract]. Paper presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, November 11-15, 2005.

  13. Zeuzem S, Sarrazin C, Wagner F, et al.: Combination therapy with the HCV protease inhibitor, SCH 503034, plus Peg-Intron in hepatitis C genotype-1 Peg-Intron non-responders: phase Ib results [abstract]. Paper presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, November 11-15, 2005. Abstract 201.

  14. Malcolm BA, Zeuzem S, Gupta S, et al.: Modeling of HCV dynamics during combination therapy with peginterferon alfa-2b and the NS3 protease inhibitor SCH 503034 [abstract]. Paper presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, November 11-15, 2005. Abstract 1266.

  15. Zhou XJ, Afdhal N, Godofsky E, et al.: Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV polymerase inhibitor: results from a phase I/II dose-escalation trial in patients with HCV-1 infection [abstract]. Paper presented at the 40th Annual Meeting of the European Association for the Study of the Liver (EASL), Paris, France, April 13-17, 2005. J Hepatol 2005, 42:229.

  16. Afdhal N, Rodriguez-Torres M, Lawitz E, et al.: Enhanced antiviral efficacy for valopicitabine (NM283) plus peginterferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial [abstract]. Paper presented at the 40th Annual Meeting of the European Association for the Study of the Liver (EASL), Paris, France, April 13-17, 2005. J Hepatol 2005, 42:39-40.

  17. McHutchison J, Bartenschlager R, Patel K, et al.: The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice [review]. J Hepatol 2006, 44:411–421. An excellent and comprehensive review of the new developments in hepatitis C treatment.

    Article  PubMed  CAS  Google Scholar 

  18. Gish RG, Nelson D, Aurora S, et al.: Virologic response and safety outcomes in therapy naïve patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a [abstract]. Paper presented at the 40th Annual Meting of the European Association for the Study of the Liver (EASL), Paris, France, April 13-17, 2005. Abstract 91.

  19. McHutchison JG, Shiffman ML, Cheung RC: A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antivir Ther 2005, 10:635–643.

    PubMed  CAS  Google Scholar 

  20. Okuse C, Rinaudo JA, Farrar K, et al.: Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res 2005, 65:23–34.

    Article  PubMed  CAS  Google Scholar 

  21. McHutchison J, Bacon B, Gordon SC, et al.: Relationships of HCV RNA responses to CPG 10101, a TLR9 agonist: pharmacodynamics and patient characteristics. Hepatology 2005, 42:249A.

    Google Scholar 

  22. Horsmans Y, Berg T, Desager JP, et al.: Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005, 42:724–731.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatology, Beth Israel Deaconess Medical Center, Liver Center, 110 Francis Street, 02215, Boston, MA, USA

    Nezam H. Afdhal MD

Authors
  1. Asim S. Khokhar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valerie Byrnes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nezam H. Afdhal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nezam H. Afdhal MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khokhar, A.S., Byrnes, V. & Afdhal, N.H. Future therapies for hepatitis C. Curr hepatitis rep 5, 121–128 (2006). https://doi.org/10.1007/s11901-006-0015-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-006-0015-y

Keywords

Search

Navigation